Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.1400 |
| Open | 0.1450 |
| Bid | 0.1350 x N/A |
| Ask | 0.1500 x N/A |
| Day's Range | 0.1400 - 0.1450 |
| 52 Week Range | 0.1000 - 0.2500 |
| Volume | |
| Avg. Volume | 16,488 |
| Market Cap | 9.776M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Apr 25, 2023 - May 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is receiving advisory services and up to $122,865 in non-dilutive research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Funding will support Rakovina Therapeutics scientists in the development of assays and animal models for evaluation of the Company’s novel classes of DNA-
- GlobeNewswire
Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates
VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the TSX Venture Exchange (the “TSXV”) to extend the expiry date of 11,414,750 common share purchase warrants (the “Warrants”) issued by the Company. The original term of the Warrants was two years and they currently expire on March 25, 2023. The Company proposes to extend the expiry date by up to 12 months (the “Warrant Extension”). No other terms o
- GlobeNewswire
Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit
VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), is pleased to announce a scientific presentation at the 6th Annual DDR Inhibitors Summit in Boston, MA. The 6th Annual DDR Inhibitors Summit, held in Boston January 24-26, 2023, brought together academic and pharmaceutical industry researchers to share progress across the preclinical and clinical DDR inhibitor landscape. The conference aims to provide an up-to-date overview of
